Coinbase Growing!

TAPINDER KATOCH INVESTMENTS
coinbase growing

Cryptocurrency brokerage firm Coinbase has met with US regulators to discuss applying for a banking license, according to an anonymous source familiar with the matter.

The Wall Street Journal reports that the firm, one of the largest in the cryptocurrency industry, met with regulators at the US Office of the Comptroller of the Currency (OCC) in early 2018 to discuss applying for a national banking charter, which preempts state-level financial regulations. Coinbase did not immediately respond to a request for comment.

Acquiring a banking license would expand the line of services that Coinbase could offer its customers and would remove the need for it to find a banking partner willing to work with a firm that offers cryptocurrency trading.

Think before mixing business, buds and blood

Boston Business Journal by Stever Robbins

Going into business with friends or family? Prepare for disaster. If you're naive -- er, I mean optimistic -- enough to think you can make it work, be sure you can handle the business pitfalls that can damage a personal relationship.

http://www.bizjournals.com/boston/stories/2003/12/29/smallb2.html?page=all

TAPINDER KATOCH INVESTMENTS

TAPINDER KATOCH INVESTMENTS
A challenge to an Environmental Protection Agency rule allowing higher concentrations of corn- based ethanol in gasoline was thrown out by a U.S. Appeals Court ruling that the groups pressing the case had no right to sue.

Making money

TAPINDER KATOCH INVESTMENTS

Top 10 NASDAQ Stocks with Highest Upside: YRCW, PPHM, CYTR, ALIM, ATHX, SNSS, NABI, VRML, TRMD, EPCT (Nov 15, 2011)

TAPINDER KATOCH INVESTMENTS
YRC Worldwide Inc. (NASDAQ:YRCW) has the 1st highest upside potential in this segment of the market. Its upside is 1568.7%. Its consensus target price is $0.69 based on the average of all estimates. Peregrine Pharmaceuticals (NASDAQ:PPHM) has the 2nd highest upside potential in this segment of the market. Its upside is 612.5%. Its consensus target price is $7.13 based on the average of all estimates. CytRx Corporation (NASDAQ:CYTR) has the 3rd highest upside potential in this segment of the market. Its upside is 558.1%. Its consensus target price is $2.57 based on the average of all estimates. Alimera Sciences Inc (NASDAQ:ALIM) has the 4th highest upside potential in this segment of the market. Its upside is 532.9%. Its consensus target price is $10.00 based on the average of all estimates. Athersys, Inc. (NASDAQ:ATHX) has the 5th highest upside potential in this segment of the market. Its upside is 443.2%. Its consensus target price is $7.23 based on the average of all estimates.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has the 6th highest upside potential in this segment of the market. Its upside is 429.4%. Its consensus target price is $6.75 based on the average of all estimates. Nabi Biopharmaceuticals (NASDAQ:NABI) has the 7th highest upside potential in this segment of the market. Its upside is 426.3%. Its consensus target price is $10.00 based on the average of all estimates. Vermillion, Inc. (NASDAQ:VRML) has the 8th highest upside potential in this segment of the market. Its upside is 387.8%. Its consensus target price is $6.00 based on the average of all estimates. Torm A/S (ADR) (NASDAQ:TRMD) has the 9th highest upside potential in this segment of the market. Its upside is 369.4%. Its consensus target price is $4.51 based on the average of all estimates. EpiCept Corporation (NASDAQ:EPCT) has the 10th highest upside potential in this segment of the market. Its upside is 363.0%. Its consensus target price is $1.67 based on the average of all estimates.